<DOC>
	<DOCNO>NCT00591617</DOCNO>
	<brief_summary>Building platform pharmacological treatment Suboxone ( buprenorphine naloxone ) , participant randomly assign one four psychosocial treatment condition .</brief_summary>
	<brief_title>Optimizing Outcomes Using Suboxone Opiate Dependence</brief_title>
	<detailed_description>The approval buprenorphine ( combine naloxone Suboxone速 ) FDA enables physician United States provide pharmacotherapy treatment opioid-dependent patient private medical setting . Buprenorphine 's wide acceptance implementation physician slower expect , however , may due part nature necessity provide comprehensive treatment opioid-dependent patient . Lessons learn methadone maintenance make clear simply provide opioid substitution address behavioral component dependence . While lack behavioral treatment facility substance abuse United States , lack integrative approach treatment opioid dependence use pharmacotherapy conjunction proven behavioral treatment strategy . Following two-week stabilization baseline period , project randomize 240 participant 4 behavioral treatment group feature cognitive behavioral therapy contingency management therapy . A universal , manual-guided psychosocial standard care buprenorphine pharmacological treatment allow ethical inclusion `` no-CBT CM therapy '' condition closely resemble current standard psychosocial care deliver opioid treatment use Suboxone速 . Behavioral therapy deliver 16 week ( study week 18 ) conjunction continue care Suboxone速 . An additional 16 week treatment use Suboxone速 ( study week 34 ) ensue CBT CM therapy provide . All participant enter buprenorphine taper return study week 52 long-term follow-up evaluation . Outcomes trial include illicit drug use ( urine drug sample collect three time per week first 18 week ) , drug craving , retention ( day protocol ) , psychiatric status ( depression , mood ) , HIV risk behavior , treatment feasibility rating . Results use recommend strategy optimize buprenorphine treatment outcome promote integration pharmacotherapy psychosocial/behavioral treatment strategy physicians behavioral treatment facility treat opioid-dependent patient .</detailed_description>
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Buprenorphine , Naloxone Drug Combination</mesh_term>
	<criteria>Participants must : 1 . Be 15 year age old . 2 . Meet DSMIVTR criterion opioid dependence . 3 . Be interested receive buprenorphine treatment opioid dependence . 4 . Be good general health , case medical/psychiatric condition need ongoing treatment , care physician provide documented willingness continue participant 's medical management coordinate care study physician . * 5 . Be agreeable capable signing inform consent . 6 . Have mean reliable transportation study period . 7 . If female child bear potential , agree use one follow method birth control surgically sterile : 1. oral contraceptive 2. patch 3. barrier ( diaphragm condom ) 4. intrauterine contraceptive system 5. levonorgestrel implant 6. medroxyprogesterone acetate contraceptive injection 7. complete abstinence sexual intercourse 8. hormonal vaginal contraceptive ring 8 . Be agreeable capable comply study procedure . Participants must : 1 . Have know sensitivity buprenorphine naloxone . 2 . Be dependent alcohol , benzodiazepine drug abuse require immediate medical attention . 3 . Have medical condition would , opinion study physician , make participation medically hazardous ( e.g. , acute hepatitis , unstable cardiovascular , liver renal disease ) . 4 . Have current pattern benzodiazepine use , assess study physician , would preclude safe participation study . 5 . Be actively involve another clinical trial . 6 . Be acutely psychotic , severely depressed , need inpatient treatment , immediate suicide risk . 7 . Be nurse pregnant female . Females become pregnant course study withdrawn study refer appropriate treatment venue ; i.e . narcotic treatment program specialty addiction clinic . 8 . Be female childbearing potential agree use medically acceptable method birth control , e.g . oral contraceptive , barrier ( diaphragm condom ) without spermicide , levonorgestrel implant , intrauterine progesterone contraceptive system , medroxyprogesterone acetate contraceptive injection , complete abstinence . 9 . Have pending legal action could prohibit continued participation oneyear period study participation ( could possibly result incarceration ) . 10 . Be expect leave clinic 's geographic area prior study completion ( within one year ) . 11 . Have previously randomize treatment condition study .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Opioids</keyword>
	<keyword>drug dependence</keyword>
	<keyword>drug abuse</keyword>
	<keyword>treatment</keyword>
</DOC>